Structure
atLeast majority ProS Experiment
:order disorder conflict PDB cluster ProS Pfam Domain SEG
781
order/disorder by at least rule
disorder by at least rule
order/disorder by majority rule
Seq 78-151 Hetero dimer : Q61301
Region 4ons D 78-83 disorder
Region 4ons D 84-144 order
Region 4ons D 145-151 disorder
Region 4ons B 78-82 disorder
Region 4ons B 83-103 order
Region 4ons B 104-108 disorder
Region 4ons B 109-143 order
Region 4ons B 144-151 disorder
Seq 118-149 Hetero dimer : IID50072 Complex
Region 1dow B 118-149 order
Seq 134-671 Hetero dimer : IID50006 Complex
Region 3ouw A 134-156 disorder
Region 3ouw A 157-549 order
Region 3ouw A 550-561 disorder
Region 3ouw A 562-664 order
Region 3ouw A 665-671 disorder
Seq 134-671 Hetero dimer : IID00035 Complex
Region 1v18 A 134-149 disorder
Region 1v18 A 150-550 order
Region 1v18 A 551-558 disorder
Region 1v18 A 559-664 order
Region 1v18 A 665-671 disorder
Seq 134-671 Hetero dimer : IID00102 Complex
Region 1m1e A 134-150 disorder
Region 1m1e A 151-549 order
Region 1m1e A 550-558 disorder
Region 1m1e A 559-671 order
Seq 134-671 Hetero tetramer : IID50003 Complex
Region 1i7w C 134-142 disorder
Region 1i7w C 143-551 order
Region 1i7w C 552-563 disorder
Region 1i7w C 564-663 order
Region 1i7w C 664-671 disorder
Region 1i7w A 134-148 disorder
Region 1i7w A 149-549 order
Region 1i7w A 550-563 disorder
Region 1i7w A 564-662 order
Region 1i7w A 663-671 disorder
Seq 134-671 Hetero dimer : IID50006 Complex
Region 3oux A 134-150 disorder
Region 3oux A 151-549 order
Region 3oux A 550-561 disorder
Region 3oux A 562-665 order
Region 3oux A 666-671 disorder
Region 4evt A 134-160 disorder
Region 4evt A 161-549 order
Region 4evt A 550-561 disorder
Region 4evt A 562-662 order
Region 4evt A 663-671 disorder
Region 4evp A 134-161 disorder
Region 4evp A 162-549 order
Region 4evp A 550-561 disorder
Region 4evp A 562-662 order
Region 4evp A 663-671 disorder
Region 4eva C 134-162 disorder
Region 4eva C 163-549 order
Region 4eva C 550-561 disorder
Region 4eva C 562-662 order
Region 4eva C 663-671 disorder
Region 4eva A 134-159 disorder
Region 4eva A 160-549 order
Region 4eva A 550-561 disorder
Region 4eva A 562-662 order
Region 4eva A 663-671 disorder
Region 4ev9 A 134-158 disorder
Region 4ev9 A 159-549 order
Region 4ev9 A 550-561 disorder
Region 4ev9 A 562-662 order
Region 4ev9 A 663-671 disorder
Region 4ev8 A 134-158 disorder
Region 4ev8 A 159-549 order
Region 4ev8 A 550-561 disorder
Region 4ev8 A 562-662 order
Region 4ev8 A 663-671 disorder
Region 3bct A 193-549 order
Region 3bct A 550-562 disorder
Region 3bct A 563-661 order
Region 2bct A 150-549 order
Region 2bct A 550-563 disorder
Region 2bct A 564-665 order
Seq 134-671 Hetero trimer : IID50003 Complex
Region 1i7x C 134-549 order
Region 1i7x C 550-559 disorder
Region 1i7x C 560-664 order
Region 1i7x C 665-671 disorder
Region 1i7x A 134-136 disorder
Region 1i7x A 137-552 order
Region 1i7x A 553-559 disorder
Region 1i7x A 560-665 order
Region 1i7x A 666-671 disorder
Seq 134-671 Hetero dimer : IID00035 Complex
Region 1jpp B 134-149 disorder
Region 1jpp B 150-545 order
Region 1jpp B 546-557 disorder
Region 1jpp B 558-663 order
Region 1jpp B 664-671 disorder
Region 1jpp A 134-150 disorder
Region 1jpp A 151-546 order
Region 1jpp A 547-560 disorder
Region 1jpp A 561-663 order
Region 1jpp A 664-671 disorder
Seq ProS possible 83-144
Hetero dimer : Q61301
Region 4ons B 83-103 order
Region 4ons B 109-143 order
Region 4ons D 84-144 order
Seq ProS possible 118-149
Hetero dimer : IID50072 Complex
Region 1dow B 118-149 order
142-142 Phosphotyrosine; by FYN and PTK6
64-64 Phosphotyrosine; by PTK6
41-41 Phosphothreonine; by GSK3-beta
37-37 Phosphoserine; by GSK3-beta and HIPK2
33-33 Phosphoserine; by GSK3-beta and HIPK2
29-29 Phosphoserine; by GSK3-beta
23-23 Phosphoserine; by GSK3-beta; alternate
246-246 Phosphoserine; by CDK5
552-552 Phosphoserine; by AMPK
Prediction
ProS 5-9,19-73,83-116,695-734,746-765,772-781
Disorder 1-74,84-84,554-558,684-781
Order 75-83,85-553,559-683
Function
Function in SwissProt
Key downstream component of the canonical Wnt signaling pathway (PubMed:15132997). In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes (By similarity). Involved in the regulation of cell adhesion, as component of an E-cadherin:catenin adhesion complex (PubMed:16325582, PubMed:18093941). Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML (By similarity). Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle (PubMed:21325504). Involved in chondrocyte differentiation via interaction with SOX9: SOX9-binding competes with the binding sites of TCF/LEF within CTNNB1, thereby inhibiting the Wnt signaling (PubMed:15132997).
Biological Process
See also
Diagram with PDB data
Cdh1/Ctnnb1 BETA-CATENIN/E-CADHERIN COMPLEX